Authors
Elisa Gremese, Simone Bernardi, Sara Bonazza, Marcin Nowik, Giusy Peluso, Alfonso Massara, Barbara Tolusso, Laura Messuti, Maria Concetta Miceli, Angelo Zoli, Francesco Trotta, Marcello Govoni, Gianfranco Ferraccioli
Publication date
2014/5/1
Journal
Rheumatology
Volume
53
Issue
5
Pages
875-881
Publisher
Oxford University Press
Description
Objective. The objective of this study was to determine whether BMI and gender could lead to a different response rate to anti-TNF agents in patients affected by axial SpA.
Methods. One hundred and seventy patients with active axial SpA (defined as a BASDAI ≥4) treated with an anti-TNF agent [adalimumab (ADA), etanercept (ETA), infliximab (IFX)] were retrospectively evaluated. Patients were divided according to the baseline BMI as normal weight (BMI < 25), overweight (BMI 25–30) and obese (BMI ≥ 30). After 12 months of treatment a 50% improvement of the initial BASDAI (BASDAI50) was the primary end point and BASDAI ≤1 was the secondary end point.
Results. After 12 months of anti-TNF treatment, 67.8% of men and 46.2% of women reached the BASDAI50 (P = 0.01). According to BMI categories, the rate of BASDAI50 achievement decreased from 72.8% in normal …
Scholar articles
E Gremese, S Bernardi, S Bonazza, M Nowik, G Peluso… - Rheumatology, 2014